Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

octreotide pamoate

Known as: OP LAR, Octreotide Embpnate, Octreotide Pamoate LAR(SMS 201-995) 
A synthetic long-acting octapeptide analogue of endogenous somatostatin. Octreotide pamoate binds to somatostatin receptors expressed by some… Expand
National Institutes of Health

Related topics

Related topics

6 relations
OctreotidePositive Regulation of ApoptosisReceptor Activation ProcessSomatostatin Receptor

Narrower (2)

OncoLarSMS 201-995 pa LAR

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2010
Highly Cited
2010
Targeting of the Orphan Receptor GPR35 by Pamoic Acid: A Potent Activator of Extracellular Signal-Regulated Kinase and β-Arrestin2 with Antinociceptive Activity
Known agonists of the orphan receptor GPR35 are kynurenic acid, zaprinast, 5-nitro-2-(3-phenylproplyamino) benzoic acid, and… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2005
2005
Effects of tamoxifen and octreotide LAR on the IGF-system compared with tamoxifen monotherapy.
The insulin-like growth factor (IGF)-system was evaluated in 150 breast cancer patients participating in a randomised phase III… Expand
Highly Cited
2004
Highly Cited
2004
High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours.
OBJECTIVE High-dose somatostatin analogue treatment has shown an antiproliferative effect in one study including patients with… Expand
  • table 1
  • table 2
  • table 3
  • table 4
Highly Cited
2002
Highly Cited
2002
A randomized controlled trial of octreotide pamoate long-acting release and carboplatin versus carboplatin alone in dogs with naturally occurring osteosarcoma: evaluation of insulin-like growth…
PURPOSE The purpose of this research was to determine whether insulin-like growth factor (IGF) suppression, using a long-acting… Expand
  • table 2
  • table 1
  • figure 1
  • figure 2
  • figure 4
2002
2002
A randomized, multicenter prospective trial assessing long‐acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma
Long‐acting release octreotide pamoate (OP‐LAR) is a synthetic octapeptide that can be administered monthly and whose activity is… Expand
2002
2002
The NCIC CTG MA.14 experience with the gallbladder toxicity of octreotide pamoate (oncolar) in a postmenopausal patient population undergoing adjuvant treatment for stage 1-3 breast cancer
2002
2002
Adding long-acting release octreotide pamoate to tamoxifen does not improve tumor response in advanced breast cancer
1998
1998
Microencapsulated octreotide pamoate in advanced gastrointestinal and pancreatic cancer: a phase I study.
Fourteen patients suffering from advanced colorectal (n = 7), pancreatic (n = 4) or gastric (n = 3) carcinomas received treatment… Expand
  • table 1
  • table 2
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE